U.S. review of CVS deal for Aetna may end soon: source
Tweet
Share
E-mail
FILE PHOTO: Logos of CVS and Aetna are displayed on a monitor above the floor of the New York Stock Exchange shortly after the opening bell in New York, U.S., December 5, 2017. REUTERS/Lucas Jackson
Get Alerts CVS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.5%
Revenue Growth %: +1.3%
Join SI Premium – FREE
WASHINGTON (Reuters) - The U.S. Justice Department's antitrust review of CVS Health Corp's (NYSE: CVS) planned purchase of Aetna Inc (NYSE: AET) may conclude soon, a source familiar with the review said on Monday.
That said, arranging divestitures needed to resolve antitrust concerns in the proposed transaction takes time and it is not clear that possible approval will come in September, said the source.
The $69 billion deal was announced in December.
(Reporting by Diane Bartz; Editing by Tom Brown)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Thoma Bravo's Proofpoint Is Said In Talks To Acquire Varonis - Bloomberg
- Shell Acquires interest in Gulf of America prospect
- Trimlite acquires KW Building Products to expand Mid-South reach
Create E-mail Alert Related Categories
General News, Mergers and Acquisitions, Reuters, RumorsRelated Entities
Second Curve CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
